Show simple item record

dc.contributor.authorTarancón, Raquel
dc.contributor.authorDomínguez-Andrés, Jorge
dc.contributor.authorUranga, Santiago
dc.contributor.authorFerreira, Anaísa V
dc.contributor.authorGroh, Laszlo A
dc.contributor.authorDomenech Lucas, Mirian 
dc.contributor.authorGonzalez-Camacho, Fernando 
dc.contributor.authorRiksen, Niels P
dc.contributor.authorAguilo, Nacho
dc.contributor.authorYuste, Jose Enrique 
dc.contributor.authorMartín, Carlos
dc.contributor.authorNetea, Mihai G
dc.identifier.citationPLoS Pathog. 2020 Apr 2;16(4):e1008404es_ES
dc.description.abstractAmong infectious diseases, tuberculosis is the leading cause of death worldwide, and represents a serious threat, especially in developing countries. The protective effects of Bacillus Calmette-Guerin (BCG), the current vaccine against tuberculosis, have been related not only to specific induction of T-cell immunity, but also with the long-term epigenetic and metabolic reprogramming of the cells from the innate immune system through a process termed trained immunity. Here we show that MTBVAC, a live attenuated strain of Mycobacterium tuberculosis, safe and immunogenic against tuberculosis antigens in adults and newborns, is also able to generate trained immunity through the induction of glycolysis and glutaminolysis and the accumulation of histone methylation marks at the promoters of proinflammatory genes, facilitating an enhanced response after secondary challenge with non-related bacterial stimuli. Importantly, these findings in human primary myeloid cells are complemented by a strong MTBVAC-induced heterologous protection against a lethal challenge with Streptococcus pneumoniae in an experimental murine model of pneumonia.es_ES
dc.description.sponsorshipM.G.N. was supported by an ERC Advanced grant (#833247) and by a Spinoza Grant of the Netherlands Organization for Scientific Research ( UNIZAR Team was supported by Ministry of Science and Universities Grant RTI2018-097625-B-100 ( The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.titleNew live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumoniaes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderDutch Research Council (Holanda) 
dc.contributor.funderMinisterio de Ciencia y Universidades (España) 
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) 
dc.identifier.journalPLoS pathogenses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional